Robust Single-Dose rAAV Dual-Targeting PCSK9/APOC3 via an Optimized Triple-Plasmid System for Ameliorating Mixed Hyperlipidemia

Mixed hyperlipidemia is characterized by concurrent hypercholesterolemic and hypertriglyceridemic burdens, which cannot be adequately addressed by existing single-target lipid-lowering strategies, leaving patients with considerable residual cardiovascular risk. Herein, we developed a single dual-target rAAV carrying a dual-promoter cassette simultaneously silences PCSK9 and APOC3, and established an optimized triple-plasmid packaging strategy to overcome the bottleneck imposed by its large (~ 5.3 kb) cargo. Systematic titration of the three packaging plasmids identified a three-fold increase in pHelper dosage as the optimal balance of replication and packaging resources, which elevated viral yield, restored the canonical 1:1:10 capsid stoichiometry, and markedly reduced the empty-capsid fraction.In a high-fat-diet mouse model, a single administration of this dual-target rAAV concurrently knocked down hepatic PCSK9 and APOC3, reducing serum TC by approximately 30% and TG by approximately 70%, with an approximately 40% gain in editing efficiency over the unoptimized vector. Moreover, this optimized dual-target rAAV offered superior advantages over single-target AAV in ameliorating systemic energy metabolic phenotypes, manifested as increased energy expenditure and a reduced respiratory exchange ratio. Overall, this study provides a feasible strategy for producing large-cargo dual-target rAAVs and establishes proof-of-concept for single-administration, dual-target gene therapy against mixed hyperlipidemia.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11619935/v1
Primary Topic
Virus-based gene therapy research
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Robust Single-Dose rAAV Dual-Targeting PCSK9/APOC3 via an Optimized Triple-Plasmid System for Ameliorating Mixed Hyperlipidemia

Mengjiao Deng, Ke Hu, Jia He, Yaxi Chen et al.
3 links
Research Square
Virus-based gene therapy research
preprint

Robust Single-Dose rAAV Dual-Targeting PCSK9/APOC3 via an Optimized Triple-Plasmid System for Ameliorating Mixed Hyperlipidemia

Mengjiao Deng, Ke Hu, Jia He, Yaxi Chen, Yunfei Zhao, Gang Zou, Yunyu He, Chao Yu, Liming Yang
preprint en

Abstract

Mixed hyperlipidemia is characterized by concurrent hypercholesterolemic and hypertriglyceridemic burdens, which cannot be adequately addressed by existing single-target lipid-lowering strategies, leaving patients with considerable residual cardiovascular risk. Herein, we developed a single dual-target rAAV carrying a dual-promoter cassette simultaneously silences PCSK9 and APOC3, and established an optimized triple-plasmid packaging strategy to overcome the bottleneck imposed by its large (~ 5.3 kb) cargo. Systematic titration of the three packaging plasmids identified a three-fold increase in pHelper dosage as the optimal balance of replication and packaging resources, which elevated viral yield, restored the canonical 1:1:10 capsid stoichiometry, and markedly reduced the empty-capsid fraction.In a high-fat-diet mouse model, a single administration of this dual-target rAAV concurrently knocked down hepatic PCSK9 and APOC3, reducing serum TC by approximately 30% and TG by approximately 70%, with an approximately 40% gain in editing efficiency over the unoptimized vector. Moreover, this optimized dual-target rAAV offered superior advantages over single-target AAV in ameliorating systemic energy metabolic phenotypes, manifested as increased energy expenditure and a reduced respiratory exchange ratio. Overall, this study provides a feasible strategy for producing large-cargo dual-target rAAVs and establishes proof-of-concept for single-administration, dual-target gene therapy against mixed hyperlipidemia.

Research Square
Second Affiliated Hospital of Chongqing Medical University (CN), Chongqing Medical University (CN)
National Natural Science Foundation of China, China Postdoctoral Science Foundation
Good health and well-being
Virus-based gene therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon